Loren Data's SAM Daily™

FBO DAILY - FEDBIZOPPS ISSUE OF AUGUST 24, 2018 FBO #6118
MODIFICATION

R -- Collection of plasma and serum samples from Asian subjects for a metabolomics reference sample set.

Notice Date

8/22/2018
 

Notice Type

Modification/Amendment
 

NAICS

621511 — Medical Laboratories
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
 

ZIP Code

20852
 

Solicitation Number

N02RC82570-61
 

Archive Date

9/11/2018
 

Point of Contact

KATHY D. ELLIOTT, Phone: 240-276-5570, Jolomi Omatete, Phone: 2402766561
 

E-Mail Address

ELLIOTTK@MAIL.NIH.GOV, jolomi.omatete@nih.gov
(ELLIOTTK@MAIL.NIH.GOV, jolomi.omatete@nih.gov)
 

Small Business Set-Aside

N/A
 

Description

Description The National Institutes of Health (NIH), National Cancer Institute (NCI), Division of Cancer Control and Population Sciences (DCCPS) plans to collect plasma and serum samples from Asian subjects for a metabolomics reference sample set. This is a combined synopsis/solicitation for commercial items, prepared in accordance with the format in FAR 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation: No. N02RC82570-61 includes all applicable provisions and clauses in effect through FAR FAC 2005-94 (January 19, 2017) simplified procedures for commercial items. The North American Industry Classification System code is 621511 and the business size standard is 1,250 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. It has been determined there are no opportunities to acquire green products or services for this procurement. Metabolomics is the assessment of small molecules, often defined to be only those molecules participating in cellular metabolism, within a given biological system. Metabolites include low-molecular weight compounds, such as lipids, sugars, amino acids, nucleotides. Modern methods, such as Nuclear Magnetic Resonance (NMR) and Mass Spectroscopy (MS) coupled with liquid chromatography (LC) or gas chromatography (GC), can identify and quantify a large number of metabolites simultaneously within a biospecimen, capturing its metabolomic profile. These profiles have been used to predict the risk of diabetes, diagnose prostate cancer, and identify biomarkers of Crohn's disease. There is a strong interest in applying metabolomic analysis to cancer epidemiologic studies. Unfortunately, unlike in animal studies, sample collection, storage and preparation can be highly variable across studies and even within studies. Such variability in sample processing will likely affect measured metabolite levels and induce artifacts in down-stream analyses. This creates challenges for data harmonization and replication of results. One way to address these challenges is to establish a reference sample set to allow the examination of metabolite-metabolite correlations between platforms, which provides important contextual information, especially if results fail to replicate between studies. Additionally, a reference sample set will support metabolite imputation efforts, such that metabolites missing from one platform may be imputed to the larger data set using prior data collected on inserted reference samples. Finally, quantitative information on metabolite levels in the reference sample set would make it possible to calibrate relative concentrations to absolute concentrations. The aim of this study is to collect a set of reference samples for metabolomics analyses in large-scale epidemiology studies, specifically prospective cohorts. This project will allow for the examination of metabolite-metabolite correlations between platforms to assist with data harmonization across platforms, metabolite imputation, and quantitation of metabolite levels across over 40 cohorts participating in the COnsortium of METabolomics Studies (COMETS). Membership criteria for COMETS is broad allowing any cohort to join if the study is prospective and has at least 100 participants with blood metabolomics data, including identified metabolite data, and follow-up data for disease. Thus, the membership criteria are inclusive and include cohorts from the United States, Europe, Asia, and South America. The National Cancer Institute (NCI), Division of Cancer Control and Population Sciences (DCCPS) plans to collect plasma and serum samples from Asian subjects for a metabolomics reference sample set. The Contractor shall provide adequate equipment, supplies, facilities, and scientific materials necessary for carrying out the requirements. The Contractor shall work on several key tasks, including the following: 1. The Contractor shall collect 25 mL each of serum and EDTA plasma, and 11 mL of heparinized plasma from the same 10 individual donors of Asian descent (ages 20-65 years old and residing in the US for less than 3 months). Aliquot the serum and EDTA plasma from each donor as follows: 75 X 0.15 mL, 20 X 0.25 mL, 9 x 0.4 mL, and 5 mL vial of remaining samples. Aliquot the heparinized plasma as follows: 25 X 0.15 mL, 5 X 0.25 mL, 2 x 0.4 mL. 2. The Contractor shall collect 4 mL of serum from each of the same 10 individual donors of Asian descent as collected in 1 above (ages 20-65 years old and residing in the US for less than 3 months) for 4 pooled samples. Aliquot the pooled serum and EDTA plasma from each donor as follows: 375 X 0.15 mL, 100 X 0.25 mL, 45 x 0.4 mL. Aliquot the heparinized plasma as follows: 75 X 0.15 mL, 20 X 0.25 mL, 9 x 0.4 mL. 3. The Contractor shall collect 4 mL of EDTA plasma from each of the same 10 individual donors of Asian descent as collected in 1 and 2 above (ages 20-65 years old and residing in the US for less than 3 months) for 4 pooled samples. Aliquot the pooled serum and EDTA plasma from each donor as follows: 375 X 0.15 mL, 100 X 0.25 mL, 45 x 0.4 mL. Aliquot the heparinized plasma as follows: 75 X 0.15 mL, 20 X 0.25 mL, 9 x 0.4 mL. 4. The Contractor shall collect 1 mL of heparinized plasma from the same 10 individual donors of Asian descent as collected in 1,2 and 3 above (ages 20-65 years old and residing in the US for less than 3 months) for 4 pooled samples. Aliquot the pooled serum and EDTA plasma from each donor as follows: 375 X 0.15 mL, 100 X 0.25 mL, 45 x 0.4 mL. Aliquot the heparinized plasma as follows: 75 X 0.15 mL, 20 X 0.25 mL, 9 x 0.4 mL. 5. The Contractor shall provide remaining serum, EDTA plasma and heparinized plasma separately in one vial. The volume should be a minimum of 5 mL. 6. The Contractor shall label all tubes with a unique identifier that links to subject ID, date drawn, material type (serum or plasma), material modifier (i.e. preservative type), vial type and brand, aliquot volume, volume unit, subject's age, subject's sex, subject's self-reported Asian ethnicity. The sample manifest and identifier scheme must be provided to and approved by the NCI Contracting Officer's Technical Representative (COTR) prior to sample collection. 7. The Contractor shall properly store and ship samples so that no freeze-thaw occurs. Ship samples to the NCI per the instruction of the NCI COTR. Samples should be stored in boxes appropriately slotted for the aliquot sizes, e.g. 100-well boxes for 0.5 ml tubes or 169-well boxes for 0.2 mL tubes. In addition, the Contractor must show that they have the required Institutional Review Board (IRB) and FederalWide Assurance (FWA) approvals to collect the samples. Delivery: Delivery shall be within 90 days after purchase order award. All shipping/handling and delivery fees shall be included. Evaluation Evaluation and award shall be conducted in accordance with the requirements of FAR Subpart 12.6 in conjunction with Lowest Price-Technically Acceptable (LPTA). A technically acceptable offer is one in which the Offeror complies with the requirements/technical specifications stated above, and does not take exception, nor object to any of the terms contained in this request. Offers that are not technically acceptable will not be considered further. The technical evaluation will be a determination based on information furnished by the Contractor. The Government is not responsible for locating or securing any information which is not identified in the quotation. The Government reserves the right to make an award without discussions. However, the Government reserves the right to conduct discussions if later determined by the Contracting Officer to be necessary. The Government may not be requesting revisions to quotations, so Offerors should provide their best solution and price in response to the solicitation. The Government may reject any or all offers if such action is in the public interest; accept other than the lowest offer; and waive informalities and minor irregularities in offers received. If you are providing an "equal" product, you must submit additional documentation that highlights and describes how your offering is equal, in accordance with FAR 52.211-6. Price Quotation The Offeror shall prepare a price quotation that contains all information necessary to allow for a comprehensive evaluation of the prices quoted. Specifically, your quotation must include the following: -Federal Tax Identification Number (TIN); -Data Universal Numbering System (DUNS) Number; -Business Size (e.g., small or large) The business quotation will be evaluated for reasonableness. For a price to be reasonable, it must represent a price to the Government that a prudent person would pay when consideration is given to prices in the market. Normally, price reasonableness is established through adequate price competition, but may also be determined through cost and price analysis techniques as described in FAR 15.404. SUBMISSION INFORMATION Quotations must be submitted electronically (via email) to Contract Specialist, Kathy Elliott, at Elliottk@mail.nih.gov in MS Word or Adobe Portable Document Format (PDF), no later than 2:00 PM EST, on Monday, August 27, 2018. All responses must be received by the specified due date and time in order to be considered. QUOTATIONS RECEIVED AFTER THIS DATE AND TIME WILL NOT BE CONSIDERED. No collect calls will be accepted. Please refer to solicitation no: N02RC82570-61 on all correspondence. Full text copies of the representations and certifications for other cited provisions and clauses may be obtained on line at the NCI website at http://ncioa.cancer.gov/oa-internet/reference.jsp or from Kathy Elliott, Contract Specialist at Elliottk@mail.nih.gov. OFFERORS: Offers must be submitted on an SF-1449 with a completed 52.212-3 Offeror Representations and Certifications-Commercial Items-with DUNS Number Addendum, signed by an authorized representative of the offeror OR provide a copy of the valid certification registrations of the offeror's Excluded Parties List System (EPLS) and Online Representations and Certifications Applications (ORCA) through www.sam.gov.
 

Web Link

FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02RC82570-61/listing.html)
 

Place of Performance

Address: 9609 Medical Center Drive, Rockville, Maryland, 20850, United States

Zip Code: 20850
 

Record

SN05051056-W 20180824/180822231349-2bb1435a123b2bb5bf6bb933fc553dc9 (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |